Biomarck

Biomarck Pharmaceuticals, Ltd., a clinical-stage biopharmaceutical company developing anti-inflammatory and oncological therapies that target the MARCKS protein, today announced the appointment of Dr. Graham G. Lumsden as President and Chief...

Biomarck Pharmaceuticals, Ltd., a biopharmaceutical company developing targeted anti-MARCKS technology for the treatment of ARDS [Acute Respiratory Distress Syndrome], cancer and other difficult to treat diseases, today announced new data...

BIO-11006 Demonstrated Safety and a 43 Percent Reduction in all-Cause Mortality at 28 Days in ARDS Potential Treatment for ARDS/COVID-19 Patients Biomarck Pharmaceuticals, Ltd., a biopharmaceutical company developing targeted anti-MARCKS...

Biomarck Pharmaceuticals, Ltd today announced that it is delighted to have been invited to present Phase 2 clinical data from its study in NSCLC and an update on the Phase...

Biomarck Pharmaceuticals, Ltd today announced that statistical significance (p=0.02) was achieved in improvement of Overall Response Rate (ORR) in the BIO-11006/SOC group compared to standard of care alone at 3...

Biomarck Pharmaceuticals, Ltd today announced that a Phase 2 clinical study in advanced NSCLC has commenced. This study at 10 sites in India compares standard of care therapy (SOC; pemetrexed...

Biomarck Pharmaceuticals, Ltd today announced that the first patients have been treated with BIO-11006 in a Phase 2 clinical study for patients with Acute Respiratory Distress Syndrome (ARDS). This trial...